These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22139081)

  • 21. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation.
    Vaught DB; Stanford JC; Young C; Hicks DJ; Wheeler F; Rinehart C; Sánchez V; Koland J; Muller WJ; Arteaga CL; Cook RS
    Cancer Res; 2012 May; 72(10):2672-82. PubMed ID: 22461506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
    Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
    Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.
    Shattuck DL; Miller JK; Carraway KL; Sweeney C
    Cancer Res; 2008 Mar; 68(5):1471-7. PubMed ID: 18316611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth.
    Khan IA; Yoo BH; McPhee M; Masson O; Surette A; Dakin-Hache K; Younis T; Bethune G; Rosen KV
    Breast Cancer Res; 2018 Dec; 20(1):151. PubMed ID: 30545388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitor of differentiation is overexpressed with progression of benign to malignant lesions and related with carcinoembryonic antigen-related cell adhesion molecule 1 distribution in mammary glands.
    Liu Q; Yang YM; Zhang QH; Zhang TG; Zhou Q; Zhou CJ
    Ann Diagn Pathol; 2011 Feb; 15(1):30-6. PubMed ID: 21106423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
    Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
    Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis.
    Eckert LB; Repasky GA; Ulkü AS; McFall A; Zhou H; Sartor CI; Der CJ
    Cancer Res; 2004 Jul; 64(13):4585-92. PubMed ID: 15231670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer.
    Citron F; Segatto I; Vinciguerra GLR; Musco L; Russo F; Mungo G; D'Andrea S; Mattevi MC; Perin T; Schiappacassi M; Massarut S; Marchini C; Amici A; Vecchione A; Baldassarre G; Belletti B
    Cancer Res; 2020 Mar; 80(5):1064-1077. PubMed ID: 31862778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinoma.
    Liu T; Sun B; Zhao X; Gu Q; Dong X; Yao Z; Zhao N; Chi J; Liu N; Sun R; Ma Y
    J Cell Mol Med; 2013 Jan; 17(1):116-22. PubMed ID: 23279650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling HER2 effects on cell behavior from mass spectrometry phosphotyrosine data.
    Kumar N; Wolf-Yadlin A; White FM; Lauffenburger DA
    PLoS Comput Biol; 2007 Jan; 3(1):e4. PubMed ID: 17206861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells.
    Willmarth NE; Ethier SP
    J Biol Chem; 2006 Dec; 281(49):37728-37. PubMed ID: 17035230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TNFAIP3 is required for FGFR1 activation-promoted proliferation and tumorigenesis of premalignant DCIS.COM human mammary epithelial cells.
    Yang M; Yu X; Li X; Luo B; Yang W; Lin Y; Li D; Gan Z; Xu J; He T
    Breast Cancer Res; 2018 Aug; 20(1):97. PubMed ID: 30111373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER2 overexpression and cancer targeting.
    Wang SC; Hung MC
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):115-24. PubMed ID: 11706403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
    Di Modugno F; Mottolese M; Di Benedetto A; Conidi A; Novelli F; Perracchio L; Venturo I; Botti C; Jager E; Santoni A; Natali PG; Nisticò P
    Clin Cancer Res; 2006 Mar; 12(5):1470-8. PubMed ID: 16533770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients.
    Zhao X; Mirza S; Alshareeda A; Zhang Y; Gurumurthy CB; Bele A; Kim JH; Mohibi S; Goswami M; Lele SM; West W; Qiu F; Ellis IO; Rakha EA; Green AR; Band H; Band V
    Breast Cancer Res Treat; 2012 Jul; 134(1):171-80. PubMed ID: 22270930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis.
    Pedersen K; Angelini PD; Laos S; Bach-Faig A; Cunningham MP; Ferrer-Ramón C; Luque-García A; García-Castillo J; Parra-Palau JL; Scaltriti M; Ramón y Cajal S; Baselga J; Arribas J
    Mol Cell Biol; 2009 Jun; 29(12):3319-31. PubMed ID: 19364815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation.
    Aigner A; Juhl H; Malerczyk C; Tkybusch A; Benz CC; Czubayko F
    Oncogene; 2001 Apr; 20(17):2101-11. PubMed ID: 11360194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The oncogene HER2/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumor growth and anoikis resistance.
    Whelan KA; Schwab LP; Karakashev SV; Franchetti L; Johannes GJ; Seagroves TN; Reginato MJ
    J Biol Chem; 2013 May; 288(22):15865-77. PubMed ID: 23585570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland.
    Sansone P; Storci G; Tavolari S; Guarnieri T; Giovannini C; Taffurelli M; Ceccarelli C; Santini D; Paterini P; Marcu KB; Chieco P; Bonafè M
    J Clin Invest; 2007 Dec; 117(12):3988-4002. PubMed ID: 18060036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.